-
Je něco špatně v tomto záznamu ?
Investigating the Molecular Basis for the Selective Inhibition of Aldehyde Dehydrogenase 2 by the Isoflavonoid Daidzin
TT. da Silva Cunha, FR. de Souza, P. de Sena Murteira Pinheiro, CMR. de Sant'Anna, F. Noël, TC. Costa França, CA. Manssour Fraga
Jazyk angličtina Země Spojené arabské emiráty
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
E-02/202.961/2017, E- 26/202.878/2018
Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro [FAPERJ]
465.249/2014-0
National Institute of Science and Technology in Drugs and Medicines (INCTINOFAR)
- MeSH
- aldehyddehydrogenasa metabolismus MeSH
- dopamin metabolismus MeSH
- inhibitory enzymů farmakologie MeSH
- isoflavony farmakologie MeSH
- poruchy spojené s užíváním psychoaktivních látek farmakoterapie MeSH
- simulace molekulového dockingu MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: ALDH-2 has been considered an important molecular target for the treatment of drug addiction due to its involvement in the metabolism of the neurotransmitter dopamine: however, the molecular basis for the selective inhibition of ALDH-2 versus ALDH-1 should be better investigated to enable a more pragmatic approach to the design of novel ALDH-2 selective inhibitors. OBJECTIVE: In the present study, we investigated the molecular basis for the selective inhibition of ALDH-2 by the antioxidant isoflavonoid daidzin (IC50 = 0.15 μM) compared to isoform 1 of ALDH through molecular dynamics studies and semiempirical calculations of the enthalpy of interaction. METHODS: The applied methodology consisted of performing the molecular docking of daidzin in the structures of ALDH-1 and ALDH-2 and submitting the lower energy complexes obtained to semiempirical calculations and dynamic molecular simulations. RESULTS: Daidzin in complex with ALDH-2 presented directed and more specific interactions, resulting in stronger bonds in energetic terms and, therefore, in enthalpic gain. Moreover, the hydrophobic subunits of daidzin, in a conformationally more restricted environment (such as the catalytic site of ALDH-2), promote the better organization of the water molecules when immersed in the solvent, also resulting in an entropic gain. CONCLUSION: The molecular basis of selective inhibition of ALDH-2 by isoflavonoids and related compounds could be related to a more favorable equilibrium relationship between enthalpic and entropic features. The results described herein expand the available knowledge regarding the physiopathological and therapeutic mechanisms associated with drug addiction.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22004892
- 003
- CZ-PrNML
- 005
- 20220127144844.0
- 007
- ta
- 008
- 220113s2020 ts f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/1871527319999200817153150 $2 doi
- 035 __
- $a (PubMed)32811404
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ts
- 100 1_
- $a da Silva Cunha, Thayssa Tavares $u Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazi $u Graduate Program in Pharmacology and Medicinal Chemistry, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazi
- 245 10
- $a Investigating the Molecular Basis for the Selective Inhibition of Aldehyde Dehydrogenase 2 by the Isoflavonoid Daidzin / $c TT. da Silva Cunha, FR. de Souza, P. de Sena Murteira Pinheiro, CMR. de Sant'Anna, F. Noël, TC. Costa França, CA. Manssour Fraga
- 520 9_
- $a BACKGROUND: ALDH-2 has been considered an important molecular target for the treatment of drug addiction due to its involvement in the metabolism of the neurotransmitter dopamine: however, the molecular basis for the selective inhibition of ALDH-2 versus ALDH-1 should be better investigated to enable a more pragmatic approach to the design of novel ALDH-2 selective inhibitors. OBJECTIVE: In the present study, we investigated the molecular basis for the selective inhibition of ALDH-2 by the antioxidant isoflavonoid daidzin (IC50 = 0.15 μM) compared to isoform 1 of ALDH through molecular dynamics studies and semiempirical calculations of the enthalpy of interaction. METHODS: The applied methodology consisted of performing the molecular docking of daidzin in the structures of ALDH-1 and ALDH-2 and submitting the lower energy complexes obtained to semiempirical calculations and dynamic molecular simulations. RESULTS: Daidzin in complex with ALDH-2 presented directed and more specific interactions, resulting in stronger bonds in energetic terms and, therefore, in enthalpic gain. Moreover, the hydrophobic subunits of daidzin, in a conformationally more restricted environment (such as the catalytic site of ALDH-2), promote the better organization of the water molecules when immersed in the solvent, also resulting in an entropic gain. CONCLUSION: The molecular basis of selective inhibition of ALDH-2 by isoflavonoids and related compounds could be related to a more favorable equilibrium relationship between enthalpic and entropic features. The results described herein expand the available knowledge regarding the physiopathological and therapeutic mechanisms associated with drug addiction.
- 650 _2
- $a aldehyddehydrogenasa $x metabolismus $7 D000444
- 650 _2
- $a dopamin $x metabolismus $7 D004298
- 650 _2
- $a inhibitory enzymů $x farmakologie $7 D004791
- 650 _2
- $a isoflavony $x farmakologie $7 D007529
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a poruchy spojené s užíváním psychoaktivních látek $x farmakoterapie $7 D019966
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a de Souza, Felipe Rodrigues $u Laboratory of Molecular Modeling Applied to the Chemical and Biological Defense (LMACBD), Military Institute of Engineering, Rio de Janeiro, RJ, Brazi
- 700 1_
- $a de Sena Murteira Pinheiro, Pedro $u Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazi $u Graduate Program in Pharmacology and Medicinal Chemistry, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazi
- 700 1_
- $a de Sant'Anna, Carlos Maurício Rabello $u Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazi $u Department of Fundamental Chemistry, Chemistry Institute, Federal Rural University of Rio de Janeiro, Seropédica, RJ, Brazi
- 700 1_
- $a Noël, François $u Graduate Program in Pharmacology and Medicinal Chemistry, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazi $u Laboratory of Molecular Biochemical and Pharmacology, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazi
- 700 1_
- $a Costa França, Tanos Celmar $u Laboratory of Molecular Modeling Applied to the Chemical and Biological Defense (LMACBD), Military Institute of Engineering, Rio de Janeiro, RJ, Brazi $u Center for Basic and Applied Research, Faculty of Informatics and Management, University of Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republi
- 700 1_
- $a Manssour Fraga, Carlos Alberto $u Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazi $u Graduate Program in Pharmacology and Medicinal Chemistry, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazi
- 773 0_
- $w MED00173402 $t CNS & neurological disorders drug targets $x 1996-3181 $g Roč. 19, č. 6 (2020), s. 437-447
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32811404 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127144840 $b ABA008
- 999 __
- $a ok $b bmc $g 1752185 $s 1156041
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 19 $c 6 $d 437-447 $e - $i 1996-3181 $m CNS & neurological disorders. Drug targets $n CNS Neurol Disord Drug Targets $x MED00173402
- GRA __
- $a E-02/202.961/2017, E- 26/202.878/2018 $p Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro [FAPERJ]
- GRA __
- $a 465.249/2014-0 $p National Institute of Science and Technology in Drugs and Medicines (INCTINOFAR)
- LZP __
- $a Pubmed-20220113